Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
Year: 2019
Type: article
Study design: Clinical Trial
Source: Blood
Institutions: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Universidad Complutense de Madrid, Spanish National Cancer Research Centre, Hospital Universitario 12 De Octubre, Centro de Investigación Biomédica en Red de Cáncer, Instituto de Investigación Biomédica de Salamanca, Hospital Clínic de Barcelona, Universitat de Barcelona, Centre Hospitalier Universitaire de Tours, Hôpital Bretonneau, Josep Carreras Leukaemia Research Institute, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Hôpital Saint-Louis, Navarre Institute of Health Research, Clinica Universidad de Navarra, University of Chicago Medical Center, Janssen (Netherlands), Janssen Research & Development (United States), Emory University, Winship Cancer Institute, Centre Hospitalier Universitaire de Nantes, Nantes Université
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2945434115
